



SEQUENCE LISTING

<110> Elan Pharmaceuticals, Inc.

Pharmacia & Upjohn Company

Varghese, John

Maillard, Michel

Beck, James

Baldwin, Eric

Hughes, Robert

Pulley, Shon

TenBrink, Ruth

<120> Acetyl 2-Hydroxy-1,3-Diaminoalkanes

<130> 02-793-C

<140> 10/658,959

<141> 2003-09-10

<150> 60/409,453

<151> 2002-09-10

<150> 60/452,231

<151> 2003-03-05

<150> 60/491,757

<151> 2003-08-01

<160> 9

<170> PatentIn version 3.0

<210> 1

<211> 13

<212> PRT

<213> Artificial

<220>

<223> Synthetic Peptide

<220>

<221> MISC\_FEATURE

<222> (1)..(1)

<223> N-terminal biotin

<220>

<221> MISC\_FEATURE

<222> (11)..(11)

<223> covalent attachment of oregon green

<400> 1

Ser Glu Val Asn Leu Asp Ala Glu Phe Arg Cys Lys Lys  
1 5 10

<210> 2

<211> 13

<212> PRT

<213> Artificial

<220>

<223> synthetic peptide

<220>

<221> MISC\_FEATURE

<222> (1)..(1)

<223> N-terminal biotin

<220>

<221> MISC\_FEATURE

<222> (11)..(11)

<223> covalent attachment of oregon green

<400> 2

Ser Glu Val Lys Met Asp Ala Glu Phe Arg Cys Lys Lys  
1 5 10

<210> 3

<211> 22

<212> PRT

<213> Artificial

<220>

<223> synthetic peptide

<220>

<221> MISC\_FEATURE

<222> (1)..(1)

<223> N-terminal biotin

<220>

<221> MISC\_FEATURE

<222> (20)..(20)

<223> covalent attachment of oregon green

<400> 3

Gly Leu Asn Ile Lys Thr Glu Glu Ile Ser Glu Ile Ser Tyr Glu Val  
1 5 10 15

Glu Phe Arg Cys Lys Lys  
20

<210> 4

<211> 34

<212> PRT

<213> Artificial

<220>

<223> synthetic peptide

<220>

<221> MISC\_FEATURE

<222> (1)..(1)

<223> N-terminal biotin

<220>

<221> MISC\_FEATURE

<222> (32)..(32)

<223> covalent attachment of oregon green

<400> 4

Ala Asp Arg Gly Leu Thr Thr Arg Pro Gly Ser Gly Leu Thr Asn Ile  
1 5 10 15

Lys Thr Glu Glu Ile Ser Glu Val Asn Leu Asp Ala Glu Phe Arg Cys  
20 25 30

Lys Lys

<210> 5

<211> 33

<212> PRT

<213> Artificial

<220>

<223> synthetic peptide

<220>

<221> MISC\_FEATURE

<222> (1)..(1)

<223> N-terminal biotin

<220>

<221> MISC\_FEATURE

<222> (7)..(7)

<223> oxidized cysteine

<220>

<221> MISC\_FEATURE

<222> (19)..(19)

<223> oxidized cysteine

<220>

<221> MISC\_FEATURE

<222> (31)..(31)

<223> covalent attachment of oregon green

<400> 5

Phe Val Asn Gln His Leu Cys Gly Ser His Leu Val Glu Ala Leu Tyr  
1 5 10 15

Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Pro Lys Ala Cys Lys  
20 25 30

Lys

<210> 6

<211> 33

<212> PRT

<213> Artificial

<220>

<223> synthetic peptide

<220>

<221> MISC\_FEATURE

<222> (1)..(1)

<223> N-terminal biotin

<400> 6

Cys	Gly	Gly	Ala	Asp	Arg	Gly	Leu	Thr	Thr	Arg	Pro	Gly	Ser	Gly	Leu
1				5					10					15	
Thr	Asn	Ile	Lys	Thr	Glu	Glu	Ile	Ser	Glu	Val	Asn	Leu	Asp	Ala	Glu
			20					25					30		

Phe

<210> 7

<211> 29

<212> PRT

<213> Artificial

<220>

<223> synthetic peptide

<220>

<221> MISC\_FEATURE

<222> (1)..(1)

<223> N-terminal biotin

<400> 7

Cys	Gly	Gly	Ala	Asp	Arg	Gly	Leu	Thr	Thr	Arg	Pro	Gly	Ser	Gly	Leu
1				5					10					15	
Thr	Asn	Ile	Lys	Thr	Glu	Glu	Ile	Ser	Glu	Val	Asn	Leu			
			20					25							

<210> 8

<211> 9

<212> PRT

<213> Artificial

<220>

<223> synthetic peptide

<400> 8

Ser Glu Val Asn Leu Asp Ala Glu Phe  
1 5

<210> 9

<211> 30

<212> PRT

<213> Artificial

<220>

<223> synthetic peptide

<400> 9

Ala Asp Arg Gly Leu Thr Thr Arg Pro Gly Ser Gly Leu Thr Asn Ile  
1 5 10 15

Lys Thr Glu Glu Ile Ser Glu Val Asn Leu Asp Ala Glu Phe  
20 25 30